Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis - PubMed (original) (raw)
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis
A Chiarugi et al. Neuroscience. 2001.
Abstract
Kynurenine 3-mono-oxygenase, one of the key enzymes of the "kynurenine pathway", catalyses the formation of 3-hydroxykynurenine and may direct the neo-synthesis of quinolinic and kynurenic acids. While 3-hydroxykynurenine and quinolinic acid have neurotoxic properties, kynurenic acid antagonizes excitotoxic neuronal death. Here we report that the expression and activity of kynurenine 3-mono-oxygenase significantly increased in the spinal cord of rats with experimental allergic encephalopathy, an experimental model of multiple sclerosis. As a consequence of this increase, the spinal cord content of 3-hydroxykynurenine and quinolinic acid reached neurotoxic levels. We also report that systemic administration of Ro 61-8048, a selective kynurenine 3-mono-oxygenase inhibitor, reduced the increase of both 3-hydroxykynurenine and quinolinic acid, and caused accumulation of kynurenic acid. In the brain and spinal cord of the controls, kynurenine 3-mono-oxygenase immunoreactivity was located in granules (probably mitochondria) present in the cytoplasm of both neurons and astroglial cells. In the spinal cord of rats with experimental allergic encephalopathy, however, cells with a very intense kynurenine 3-mono-oxygenase immunoreactivity, also able to express class II major histocompatibility complex and inducible nitric oxide synthase, were found in perivascular, subependymal and subpial locations. These cells (most probably macrophages) were responsible for the large increase in 3-hydroxykynurenine and quinolinic acid found in the spinal cords of affected animals. The results show that cells of the immune system are responsible for the increased formation of 3-hydroxykynurenine and quinolinic acid, two neurotoxic metabolites that accumulate in the central nervous system of rats with experimental allergic encephalomyelitis. They also demonstrate that selective kynurenine 3-mono-oxygenase inhibitors reduce the neo-synthesis of these toxins.
Similar articles
- Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
Carpenedo R, Meli E, Peruginelli F, Pellegrini-Giampietro DE, Moroni F. Carpenedo R, et al. J Neurochem. 2002 Sep;82(6):1465-71. doi: 10.1046/j.1471-4159.2002.01090.x. J Neurochem. 2002. PMID: 12354294 - Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Zarzecki MS, Cattelan Souza L, Giacomeli R, Silva MRP, Prigol M, Boeira SP, Jesse CR. Zarzecki MS, et al. Neurochem Res. 2020 Dec;45(12):2959-2977. doi: 10.1007/s11064-020-03144-6. Epub 2020 Oct 11. Neurochem Res. 2020. PMID: 33040279 - Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis.
Saito K, Heyes MP. Saito K, et al. Adv Exp Med Biol. 1996;398:485-92. Adv Exp Med Biol. 1996. PMID: 8906309 Review. No abstract available. - The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L, Yu JT, Tan L. Tan L, et al. J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29. J Neurol Sci. 2012. PMID: 22939820 Review.
Cited by
- Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway.
de Oliveira FR, Fantucci MZ, Adriano L, Valim V, Cunha TM, Louzada-Junior P, Rocha EM. de Oliveira FR, et al. Int J Mol Sci. 2018 Dec 8;19(12):3953. doi: 10.3390/ijms19123953. Int J Mol Sci. 2018. PMID: 30544839 Free PMC article. Review. - Kynurenine-3-monooxygenase: A new direction for the treatment in different diseases.
Lu Y, Shao M, Wu T. Lu Y, et al. Food Sci Nutr. 2020 Jan 20;8(2):711-719. doi: 10.1002/fsn3.1418. eCollection 2020 Feb. Food Sci Nutr. 2020. PMID: 32148781 Free PMC article. Review. - Metabolic pathways as possible therapeutic targets for progressive multiple sclerosis.
Heidker RM, Emerson MR, LeVine SM. Heidker RM, et al. Neural Regen Res. 2017 Aug;12(8):1262-1267. doi: 10.4103/1673-5374.213542. Neural Regen Res. 2017. PMID: 28966637 Free PMC article. Review. - Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis.
Correale J. Correale J. Front Immunol. 2021 Jan 20;11:600428. doi: 10.3389/fimmu.2020.600428. eCollection 2020. Front Immunol. 2021. PMID: 33552055 Free PMC article. Review. - Meningeal dendritic cells drive neuropathic pain through elevation of the kynurenine metabolic pathway in mice.
Maganin AG, Souza GR, Fonseca MD, Lopes AH, Guimarães RM, Dagostin A, Cecilio NT, Mendes AS, Gonçalves WA, Silva CE, Fernandes Gomes FI, Mauriz Marques LM, Silva RL, Arruda LM, Santana DA, Lemos H, Huang L, Davoli-Ferreira M, Santana-Coelho D, Sant'Anna MB, Kusuda R, Talbot J, Pacholczyk G, Buqui GA, Lopes NP, Alves-Filho JC, Leão RM, O'Connor JC, Cunha FQ, Mellor A, Cunha TM. Maganin AG, et al. J Clin Invest. 2022 Dec 1;132(23):e153805. doi: 10.1172/JCI153805. J Clin Invest. 2022. PMID: 36227694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials